Literature DB >> 7726891

The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.

P Boissonnat1, P Salen, J Guidollet, R Ferrera, G Dureau, J Ninet, S Renaud, M de Lorgeril.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7726891

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  12 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Fibrate therapy and renal function.

Authors:  Domenic A Sica
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

Review 4.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 5.  Fenofibrate: a review of its use in dyslipidaemia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

6.  Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats.

Authors:  Ying Qin; Ya-ping Tian
Journal:  Lipids Health Dis       Date:  2010-07-26       Impact factor: 3.876

Review 7.  Management of hyperlipidaemia associated with heart transplantation.

Authors:  Klaus Wenke
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.

Authors:  Anders Asberg
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.

Authors:  Josyf C Mychaleckyj; Timothy Craven; Uma Nayak; John Buse; John R Crouse; Marshall Elam; Kent Kirchner; Daniel Lorber; Santica Marcovina; William Sivitz; Joann Sperl-Hillen; Denise E Bonds; Henry N Ginsberg
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.